TMS Therapy · Hayward, CA
The Deep TMS vs. standard rTMS question is one of the most common ones I get from patients comparing TMS clinics. The marketing on both sides can muddy what is actually a relatively clean distinction: two FDA-cleared technologies, two different coil designs, overlapping but distinct indications, and roughly comparable efficacy for the indications they share.
The short version: standard rTMS uses a figure-8 coil that delivers focal stimulation to a small cortical region — typically the left dorsolateral prefrontal cortex (DLPFC). Deep TMS uses a helmet-style “H-coil” (most often the H1 coil for depression) that delivers broader, deeper stimulation across the prefrontal cortex and connected structures. Both are FDA-cleared for major depression. Deep TMS has additional FDA clearances for OCD (H7 coil) and smoking cessation (H4 coil) that standard rTMS does not.[1][2]
Two FDA-cleared technologies. Comparable efficacy for depression. Distinct indications at the margins.
The coil designs and what they actually do
Standard rTMS uses a figure-8 coil placed against the scalp over the target cortical region. The figure-8 shape produces a focal magnetic field — most of the stimulation reaches a region about 1–2 cm in diameter, 1.5–2 cm deep into the cortex. For depression, the target is the left DLPFC, identified using either the 5.5-cm rule, the Beam F3 method, or MRI-guided neuronavigation.[1]
Deep TMS uses one of several H-coil designs housed in a helmet-style positioning system. The H1 coil for depression produces a broader, less focal field that reaches roughly 3–4 cm deep into the cortex and stimulates a wider area than the figure-8. The H7 coil for OCD targets the medial prefrontal and anterior cingulate cortex. The H4 coil for smoking cessation targets a broader frontal/insular field.[3]
“Deep” in the name refers to the depth of effective stimulation, not to the depth of patient experience. Both technologies are non-invasive, awake, and outpatient. Both deliver thousands of magnetic pulses per session.
What the efficacy data actually shows
For major depression, the head-to-head comparison is closer than either marketing department wants to admit.
Standard rTMS (figure-8, 10-Hz left DLPFC): Across major network meta-analyses, response rates cluster around 40–55% and remission around 25–35% in treatment-resistant depression. The Mutz 2019 BMJ network meta-analysis of 113 trials in 6,750 patients found HFL rTMS odds ratio 3.17 versus sham.[4]
Deep TMS (H1 coil): A 2024 meta-analysis of 5 randomized controlled trials in 507 treatment-resistant depression patients found response rates of 45.3% with Deep TMS versus 24.2% with sham, and remission of 38.3% versus 14.4%.[5] These numbers are comparable to standard rTMS in similar populations, with overlapping confidence intervals.
The honest takeaway: for treatment-resistant depression, Deep TMS and standard rTMS produce broadly similar response and remission rates. Differences exist at the margins, and individual patients may respond better to one or the other, but no large head-to-head trial has demonstrated a clear superiority of one approach for the average MDD patient.[2]
Same mechanism. Different coils. Distinct indications.
| Standard rTMS | Deep TMS | |
|---|---|---|
| Coil design | Figure-8 (focal) | H-coil helmet (broader, deeper) |
| Stimulation depth | ~1.5–2 cm | ~3–4 cm |
| Session time | 3 min (iTBS) or 37.5 min (10-Hz) | ~20 min |
| MDD response rate | ~40–55% (NMA)[4] | ~45% (Lan 2024)[5] |
| MDD remission | ~25–35%[4] | ~38%[5] |
| OCD clearance | No | Yes — H7 coil (2018) |
| Smoking cessation | No | Yes — H4 coil (2020) |
Where Deep TMS has unique FDA clearance
OCD and smoking cessation — Deep TMS only.
OCD: The Deep TMS H7 coil received FDA clearance for OCD in 2018 based on a multicenter RCT showing significant YBOCS reductions versus sham. Standard figure-8 coil TMS does not have an OCD indication. If you’re a patient with treatment-resistant OCD seeking TMS, Deep TMS H7 is the FDA-cleared option.[3]
Smoking cessation: The Deep TMS H4 coil received FDA clearance for smoking cessation in 2020. Standard rTMS does not have this indication.[3]
Session experience and time
Practically speaking, the two technologies feel different in the chair.
Standard 10-Hz rTMS: ~37.5 minutes of active stimulation per session. ~25–60 minutes door-to-door. Patients describe a focal tapping sensation on the scalp at the target site.
Standard iTBS: ~3 minutes of active stimulation per session. Same focal sensation, much shorter duration. Same FDA-cleared protocol as 10-Hz, established as non-inferior in the THREE-D trial of 414 patients.[6]
Deep TMS (H1 coil for MDD): ~20 minutes of active stimulation per session. Patients describe a broader scalp sensation since the H-coil covers a larger area. Some patients prefer the broader, less focal feel; others prefer the standard figure-8’s more targeted feeling.
Headache, scalp soreness, and dizziness rates are similar between the two technologies in head-to-head safety data. Seizure rates are similarly low for both at ~1 per 30,000–100,000 sessions when used with standard parameters.[7]
How clinicians decide which to offer
In a clinic that offers both, the decision usually comes down to four practical factors.
Indication. OCD → Deep TMS H7. Smoking cessation → Deep TMS H4. Depression → either works.
Patient anatomy and history. Patients with thicker skull tables, broader prefrontal cortex variability, or anatomical considerations that complicate focal targeting may benefit from Deep TMS’s broader field. Patients with prior TMS non-response on one technology sometimes respond to the other.
Session length preferences. Patients who want shorter sessions usually do best with iTBS (3 min). Patients who prefer the broader Deep TMS sensation tolerate the 20-min session well. Standard 10-Hz at 37.5 min is the longest.
Insurance coverage. Most commercial insurance covers both Deep TMS and standard rTMS for FDA-cleared indications. Verify before committing — some plans have specific coil restrictions.
How clinicians pick Deep TMS vs standard rTMS in practice.
- Indication. OCD → Deep TMS H7 (only FDA-cleared option). Smoking cessation → Deep TMS H4. MDD → either works.
- Anatomy and prior response. Thicker skulls, broader cortical variability, or prior non-response to one technology may favor switching.
- Session length preference. Want shortest? iTBS (3 min). Prefer broader sensation? Deep TMS (20 min). Standard 10-Hz is longest (37.5 min).
- Insurance coverage. Most plans cover both for FDA-cleared indications, but some have specific coil restrictions. Verify before committing.
The bottom line
For major depression, Deep TMS and standard rTMS deliver broadly comparable response and remission rates. The mechanism of action — neuroplastic changes in prefrontal-limbic circuits — is the same. The coil designs differ, the session lengths differ, and the FDA-cleared indications partially differ (OCD and smoking cessation are Deep TMS only).
Choose your clinic based on which technologies they offer, what your specific indication is, your insurance coverage, and your scheduling needs — not based on marketing claims that one modality is dramatically better than the other for the average patient.[2][5]
If you’re in Hayward or anywhere in the East Bay and you want to discuss which TMS technology fits your specific situation, that’s what a consultation is for.
An evidence-based TMS consultation in Hayward, CA.
Exxceed Wellness offers both Deep TMS and standard rTMS. We help you match the right technology to your specific diagnosis, anatomy, schedule, and insurance — without marketing-driven promises about either modality being dramatically superior.
Founder, Exxceed Wellness · Hayward, CA · Telehealth across California
References
- McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):16cs10905. PMID: 28541649. doi:10.4088/JCP.16cs10905.
- Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. 2020;131(2):474-528. PMID: 31901449. doi:10.1016/j.clinph.2019.11.002.
- Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations: Expert Guidelines. Clin Neurophysiol. 2021;132(1):269-306. PMID: 33243615. doi:10.1016/j.clinph.2020.10.003.
- Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for major depressive episodes: systematic review and network meta-analysis. BMJ. 2019;364:l1079. PMID: 30917990. doi:10.1136/bmj.l1079.
- Lan XJ, Yang XH, Mo Y, et al. The efficacy and safety of deep transcranial magnetic stimulation for treatment-resistant depression: systematic review and meta-analysis. Asian J Psychiatr. 2024;96:104032. PMID: 38574492. doi:10.1016/j.ajp.2024.104032.
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D). Lancet. 2018;391(10131):1683-1692. PMID: 29726344. doi:10.1016/S0140-6736(18)30295-2.
- Caulfield KA, Fleischmann HH, George MS, McTeague LM. A transdiagnostic review of safety, efficacy, and parameter space in accelerated TMS. J Psychiatr Res. 2022;152:384-396. PMID: 35816982. doi:10.1016/j.jpsychires.2022.06.038.
Comments are closed